Exploring a new type of cancer therapy that activates the immune response without damaging DNA.
Official title: Induction of interferon response by chromatin damaging anti-cancer therapy
Funded at Roswell Park Cancer Institute Corp · NIH-10991726 · Data updated 2026-11-12
This study is exploring a new way to treat cancer using special drugs called curaxins that help your immune system fight the cancer without causing the usual side effects of traditional treatments, so you might feel better while getting more effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $396,881 |
| NIH project number | 5R01CA266216-02 |
| Project ID | NIH-10991726 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer who are seeking alternative treatment options that minimize toxicity.
✕Less likely to help
Patients who do not have cancer or those whose cancer is not responsive to immune-based therapies may not benefit from this research.
What this research studies
This research investigates a novel approach to cancer treatment that focuses on chromatin damage rather than traditional DNA damage. By using a new class of drugs called curaxins, which induce an immune response without the harmful effects associated with DNA-targeting therapies, the study aims to enhance the effectiveness of cancer treatments while reducing toxicity. The research will involve understanding how these drugs activate interferon signaling, which is crucial for boosting anti-tumor immunity. Patients may benefit from therapies that are more effective and have fewer side effects compared to conventional treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic cancer therapies that harness the body's immune response.
How similar studies have gone: Other research has shown promising results with similar immune-based approaches, indicating potential for success in this novel strategy.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Gurova, Katerina V — Roswell Park Cancer Institute Corp
- Study coordinator: Gurova, Katerina V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.